144 related articles for article (PubMed ID: 32717613)
1. Development of chiral fluorinated alkyl derivatives of emixustat as drug candidates for the treatment of retinal degenerative diseases.
Blum E; Zhang J; Korshin E; Palczewski K; Gruzman A
Bioorg Med Chem Lett; 2020 Sep; 30(18):127421. PubMed ID: 32717613
[TBL] [Abstract][Full Text] [Related]
2. Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity.
Bavik C; Henry SH; Zhang Y; Mitts K; McGinn T; Budzynski E; Pashko A; Lieu KL; Zhong S; Blumberg B; Kuksa V; Orme M; Scott I; Fawzi A; Kubota R
PLoS One; 2015; 10(5):e0124940. PubMed ID: 25970164
[TBL] [Abstract][Full Text] [Related]
3. Molecular pharmacodynamics of emixustat in protection against retinal degeneration.
Zhang J; Kiser PD; Badiee M; Palczewska G; Dong Z; Golczak M; Tochtrop GP; Palczewski K
J Clin Invest; 2015 Jul; 125(7):2781-94. PubMed ID: 26075817
[TBL] [Abstract][Full Text] [Related]
4. Rational Alteration of Pharmacokinetics of Chiral Fluorinated and Deuterated Derivatives of Emixustat for Retinal Therapy.
Blum E; Zhang J; Zaluski J; Einstein DE; Korshin EE; Kubas A; Gruzman A; Tochtrop GP; Kiser PD; Palczewski K
J Med Chem; 2021 Jun; 64(12):8287-8302. PubMed ID: 34081480
[TBL] [Abstract][Full Text] [Related]
5. The novel visual cycle inhibitor (±)-RPE65-61 protects retinal photoreceptors from light-induced degeneration.
Wang Y; Ma X; Muthuraman P; Raja A; Jayaraman A; Petrukhin K; Cioffi CL; Ma JX; Moiseyev G
PLoS One; 2022; 17(10):e0269437. PubMed ID: 36227868
[TBL] [Abstract][Full Text] [Related]
6. Rational Tuning of Visual Cycle Modulator Pharmacodynamics.
Kiser PD; Zhang J; Badiee M; Kinoshita J; Peachey NS; Tochtrop GP; Palczewski K
J Pharmacol Exp Ther; 2017 Jul; 362(1):131-145. PubMed ID: 28476927
[TBL] [Abstract][Full Text] [Related]
7. All-trans-Retinaldehyde Contributes to Retinal Vascular Permeability in Ischemia Reperfusion.
Dreffs A; Lin CM; Liu X; Shanmugam S; Abcouwer SF; Kern TS; Antonetti DA
Invest Ophthalmol Vis Sci; 2020 Jun; 61(6):8. PubMed ID: 32492112
[TBL] [Abstract][Full Text] [Related]
8. Emixustat Reduces Metabolic Demand of Dark Activity in the Retina.
Kubota R; Calkins DJ; Henry SH; Linsenmeier RA
Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4924-4930. PubMed ID: 31770432
[TBL] [Abstract][Full Text] [Related]
9. Phase ii, randomized, placebo-controlled, 90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular degeneration.
Dugel PU; Novack RL; Csaky KG; Richmond PP; Birch DG; Kubota R
Retina; 2015 Jun; 35(6):1173-83. PubMed ID: 25932553
[TBL] [Abstract][Full Text] [Related]
10. Tuning the Metabolic Stability of Visual Cycle Modulators through Modification of an RPE65 Recognition Motif.
Bassetto M; Zaluski J; Li B; Zhang J; Badiee M; Kiser PD; Tochtrop GP
J Med Chem; 2023 Jun; 66(12):8140-8158. PubMed ID: 37279401
[TBL] [Abstract][Full Text] [Related]
11. Catalytic mechanism of a retinoid isomerase essential for vertebrate vision.
Kiser PD; Zhang J; Badiee M; Li Q; Shi W; Sui X; Golczak M; Tochtrop GP; Palczewski K
Nat Chem Biol; 2015 Jun; 11(6):409-15. PubMed ID: 25894083
[TBL] [Abstract][Full Text] [Related]
12. A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration.
Shin Y; Moiseyev G; Petrukhin K; Cioffi CL; Muthuraman P; Takahashi Y; Ma JX
Biochim Biophys Acta Mol Basis Dis; 2018 Jul; 1864(7):2420-2429. PubMed ID: 29684583
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of retinal disease with visual cycle modulators.
Hussain RM; Gregori NZ; Ciulla TA; Lam BL
Expert Opin Pharmacother; 2018 Apr; 19(5):471-481. PubMed ID: 29542350
[TBL] [Abstract][Full Text] [Related]
14. Vitamin A aldehyde-taurine adduct and the visual cycle.
Kim HJ; Zhao J; Sparrow JR
Proc Natl Acad Sci U S A; 2020 Oct; 117(40):24867-24875. PubMed ID: 32958638
[TBL] [Abstract][Full Text] [Related]
15. Retinoid isomerase inhibitors impair but do not block mammalian cone photoreceptor function.
Kiser PD; Zhang J; Sharma A; Angueyra JM; Kolesnikov AV; Badiee M; Tochtrop GP; Kinoshita J; Peachey NS; Li W; Kefalov VJ; Palczewski K
J Gen Physiol; 2018 Apr; 150(4):571-590. PubMed ID: 29500274
[TBL] [Abstract][Full Text] [Related]
16. Ciliary neurotrophic factor (CNTF) protects retinal cone and rod photoreceptors by suppressing excessive formation of the visual pigments.
Li S; Sato K; Gordon WC; Sendtner M; Bazan NG; Jin M
J Biol Chem; 2018 Sep; 293(39):15256-15268. PubMed ID: 30115683
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 9-cis-retinyl acetate therapy in Rpe65-/- mice.
Maeda T; Maeda A; Casadesus G; Palczewski K; Margaron P
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4368-78. PubMed ID: 19407008
[TBL] [Abstract][Full Text] [Related]
18. Vitamin A and Vision.
Saari JC
Subcell Biochem; 2016; 81():231-259. PubMed ID: 27830507
[TBL] [Abstract][Full Text] [Related]
19. Vitamin A derivatives as treatment options for retinal degenerative diseases.
Perusek L; Maeda T
Nutrients; 2013 Jul; 5(7):2646-66. PubMed ID: 23857173
[TBL] [Abstract][Full Text] [Related]
20. Cone outer segment morphology and cone function in the Rpe65-/- Nrl-/- mouse retina are amenable to retinoid replacement.
Kunchithapautham K; Coughlin B; Crouch RK; Rohrer B
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4858-64. PubMed ID: 19407011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
